Evidence map›Paper›PMID 36940632›Full record

ArticleBiosensors & bioelectronics2023

Ultra-sensitive label-free SERS biosensor with high-throughput screened DNA aptamer for universal detection of SARS-CoV-2 variants from clinical samples.

Ki Sung Park, Anna Choi, Hyun Jung Kim, Insu Park, Mi-Suk Eom, Sang-Gu Yeo, Ryeo Gang Son, Tae-In Park, Gyudo Lee, Hyongsok Tom Soh and 2 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biosensors & bioelectronics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
8.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 57 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. SERS-based microdroplet platform for high-throughput screening ofFrontiers in bioengineering and biotechnology · 2024
    Article
  17. Review
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 2 countries.

Ki Sung ParkDepartment of Biotechnology and Bioinformatics, Korea University, Sejong, 30019, Republic of Korea.
Anna ChoiDepartment of Biotechnology and Bioinformatics, Korea University, Sejong, 30019, Republic of Korea.
Hyun Jung KimDepartment of Biotechnology and Bioinformatics, Korea University, Sejong, 30019, Republic of Korea; Department of Medical Device, Korea Institute of Machinery and Materials (KIMM), Daegu, 42994, Republic of Korea.
Insu ParkDepartment of Biotechnology and Bioinformatics, Korea University, Sejong, 30019, Republic of Korea; Department of Biomedical Engineering, Konyang University, Daejeon, 35365, Republic of Korea.
Mi-Suk EomDivision of Infectious Diseases, Sejong Institute of Health & Environment, Sejong, 30015, Republic of Korea.
Sang-Gu YeoDivision of Infectious Diseases, Sejong Institute of Health & Environment, Sejong, 30015, Republic of Korea.
Ryeo Gang SonDepartment of Biotechnology and Bioinformatics, Korea University, Sejong, 30019, Republic of Korea.
Tae-In ParkDepartment of Biotechnology and Bioinformatics, Korea University, Sejong, 30019, Republic of Korea.
Gyudo LeeDepartment of Biotechnology and Bioinformatics, Korea University, Sejong, 30019, Republic of Korea.
Hyongsok Tom SohDepartment of Electrical Engineering, Stanford University, Stanford, CA, 94305, USA; Department of Radiology, Stanford University, Stanford, CA, 94305, USA.
Yoochan HongDepartment of Medical Device, Korea Institute of Machinery and Materials (KIMM), Daegu, 42994, Republic of Korea. Electronic address: ychong1983@kimm.re.kr.
Seung Pil PackDepartment of Biotechnology and Bioinformatics, Korea University, Sejong, 30019, Republic of Korea. Electronic address: spack@korea.ac.kr.
Korea University · KRSejong Institute · KRKonyang University · KRKorea Institute of Machinery & Materials · KRStanford University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

COVID-19, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has caused an ongoing global pandemic with economic and social disruption. Moreover, the virus has persistently and rapidly evolved into novel lineages with mutations. The most effective strategy to control the pandemic is suppressing virus spread through early detection of infections. Therefore, developing a rapid, accurate, easy-to-use diagnostic platform against SARS-CoV-2 variants of concern remains necessary. Here, we developed an ultra-sensitive label-free surface-enhanced Raman scattering-based aptasensor as a countermeasure for the universal detection of SARS-CoV-2 variants of concern. In this aptasensor platform, we discovered two DNA aptamers that enable binding to SARS-CoV-2 spike protein via the Particle Display, a high-throughput screening approach. These showed high affinity that exhibited dissociation constants of 1.47 ± 0.30 nM and 1.81 ± 0.39 nM. We designed a combination with the aptamers and silver nanoforest for developing an ultra-sensitive SERS platform and achieved an attomolar (10

Indexed as

Aptamers, NucleotideBiosensing TechniquesCOVID-19HumansSARS-CoV-2Spike Glycoprotein, CoronavirusAptamers, NucleotideSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2Label-free SERS biosensorParticle displaySARS-CoV-2 spike binding aptamerSERS-based aptasensorSilver nanoforest

Identifiers

PMID36940632
PMCPMC9993738
OpenAlexW4323545973

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.